Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alto Neuroscience (ANRO) PT Lowered to $10 at Baird
October 23, 2024 6:24 AM EDTBaird analyst Brian Skorney lowered the price target on Alto Neuroscience (NYSE: ANRO) to $10.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "Lowering price target to $10 on ALTO-100 failure. Alto's first shot at its precision psychiatry approach failed to materialize... More
